Everolimus
- Generic Name
- Everolimus
- Brand Names
- Afinitor, Votubia, Zortress
- Drug Type
- Small Molecule
- Chemical Formula
- C53H83NO14
- CAS Number
- 159351-69-6
- Unique Ingredient Identifier
- 9HW64Q8G6G
- Background
Everolimus is a derivative of Rapamycin (sirolimus), and works similarly to Rapamycin as an mTOR (mammalian target of rapamycin) inhibitor. It is currently used as an immunosuppressant to prevent rejection of organ transplants. In a similar fashion to other mTOR inhibitors Everolimus' effect is solely on the mTORC1 protein and not on the mTORC2 protein.
- Indication
Everolimus is indicated for the treatment of postmenopausal women with advanced hormone receptor-positive, HER2-negative breast cancer (advanced HR+ BC) in combination with exemestane, after failure of treatment with letrozole or anastrozole.
Indicated for the treatment of adult patients with progressive neuroendocrine tumors of pancreatic origin (PNET) with unresectable, locally advanced or metastatic disease.
Indicated for the treatment of adult patients with advanced renal cell carcinoma (RCC) after failure of treatment with sunitinib or sorafenib.
Indicated for the treatment of adult patients with renal angiomyolipoma and tuberous sclerosis complex (TSC), not requiring immediate surgery.
Indicated in pediatric and adult patients with tuberous sclerosis complex (TSC) for the treatment of subependymal giant cell astrocytoma (SEGA) that requires therapeutic intervention but cannot be curatively resected.
- Associated Conditions
- Heart Transplant Rejection, Kidney Transplant Rejection, Liver Transplant Rejection, Progressive Neuroendocrine Tumors of pancreatic origin, Renal angiomyolipoma, tuberous sclerosis complex, Subependymal giant cell astrocytoma, tuberous sclerosis complex, Waldenstrom's Macroglobulinemia Refractory, Advanced Carcinoid tumor, Locally advanced Progressive Neuroendocrine Tumors of gastrointestinal origin, Locally advanced lung origin Progressive Neuroendocrine Tumors, Metastatic gastrointestinal origin Progressive Neuroendocrine Tumors, Metastatic lung origin Progressive Neuroendocrine Tumors, Refractory Advanced Renal Cell Carcinoma, Refractory, advanced Breast cancer, Unresectable gastrointestinal origin Progressive Neuroendocrine Tumors, Unresectable lung origin Progressive Neuroendocrine Tumors
- Associated Therapies
- -
Everolimus in Combination With Imatinib Mesylate in Treating Patients With Locally Advanced, Locally Recurrent, or Metastatic Soft Tissue Sarcoma
- First Posted Date
- 2011-01-24
- Last Posted Date
- 2014-10-08
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 14
- Registration Number
- NCT01281865
- Locations
- 🇺🇸
Memorial Sloan-Kettering Cancer Center, New York, New York, United States
Comparison of Immunosuppression on Progression of Arteriosclerosis in Renal Transplantation
- First Posted Date
- 2011-01-13
- Last Posted Date
- 2017-08-07
- Lead Sponsor
- Dianet Dialysis Centers
- Target Recruit Count
- 13
- Registration Number
- NCT01276834
- Locations
- 🇳🇱
University Medical Center Utrecht, Utrecht, Netherlands
Pasireotide & Everolimus in Adult Patients With Radioiodine-Refractory Differentiated & Medullary Thyroid Cancer
- Conditions
- Interventions
- First Posted Date
- 2011-01-05
- Last Posted Date
- 2021-02-17
- Lead Sponsor
- Emory University
- Target Recruit Count
- 42
- Registration Number
- NCT01270321
- Locations
- 🇺🇸
Emory University Winship Cancer Institute, Atlanta, Georgia, United States
🇺🇸University of Pittsburgh Cancer Institute, Pittsburgh, Pennsylvania, United States
🇺🇸Emory University Hospital Midtown, Atlanta, Georgia, United States
Immediate Conversion From Tacrolimus to Everolimus in Stable Maintenance Renal Transplant Recipients
- First Posted Date
- 2011-01-04
- Last Posted Date
- 2017-02-24
- Lead Sponsor
- Novartis Pharmaceuticals
- Registration Number
- NCT01269684
- Locations
- 🇨🇭
Novartis Investigative Site, Zurich, Switzerland
SCHEDULE - Scandinavian Heart Transplant Everolimus de Novo Study With Early Calcineurin Inhibitor (CNI) Avoidance
- First Posted Date
- 2010-12-24
- Last Posted Date
- 2015-06-10
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 115
- Registration Number
- NCT01266148
- Locations
- 🇸🇪
Novartis Investigative Site, Lund, Sweden
Open Label, Single Arm Trial to Characterize Patients With Metastatic RCC Treated With Everolimus After Failure of the First VEGF-targeted Therapy (MARC-2)
- Conditions
- Interventions
- First Posted Date
- 2010-12-24
- Last Posted Date
- 2017-11-14
- Lead Sponsor
- iOMEDICO AG
- Target Recruit Count
- 64
- Registration Number
- NCT01266837
- Locations
- 🇩🇪
Klinik für Innere Medizin (Tumorforschung), Universitätsklinikum Essen, Essen, Germany
🇩🇪Urologie - Waldkrankenhaus St. Marien, Erlangen, Germany
🇩🇪Klinik und Poliklinik für Urologie , Universitätsklinikum Carl Gustav Carus der Technischen Universität Dresden, Dresden, Germany
Study of Everolimus and Sorafenib in Patients With Advanced Thyroid Cancer Who Progressed on Sorafenib Alone
- First Posted Date
- 2010-12-21
- Last Posted Date
- 2021-10-26
- Lead Sponsor
- Thomas Jefferson University
- Target Recruit Count
- 35
- Registration Number
- NCT01263951
- Locations
- 🇺🇸
Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania, United States
Everolimus for Patients With Relapsed/Refractory Germ Cell Cancer
- First Posted Date
- 2010-11-17
- Last Posted Date
- 2015-02-25
- Lead Sponsor
- Hannover Medical School
- Target Recruit Count
- 25
- Registration Number
- NCT01242631
- Locations
- 🇩🇪
Hannover Medical School, Hannover, Germany
🇩🇪Universitatsklinikum Hamburg-Eppendorf, Hamburg, Germany
🇩🇪Klinikum Harlaching München, München, Germany
Akt Inhibitor MK2206 or Everolimus in Treating Patients With Refractory Kidney Cancer
- First Posted Date
- 2010-11-11
- Last Posted Date
- 2019-10-10
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 43
- Registration Number
- NCT01239342
- Locations
- 🇺🇸
USC / Norris Comprehensive Cancer Center, Los Angeles, California, United States
🇺🇸Tower Cancer Research Foundation, Beverly Hills, California, United States
🇺🇸University of California Davis Comprehensive Cancer Center, Sacramento, California, United States
Cytokines Evaluation in Early Calcineurin Inhibitors Withdrawn on Renal Transplant
- First Posted Date
- 2010-11-11
- Last Posted Date
- 2020-02-07
- Lead Sponsor
- Andre Barreto Pereira
- Target Recruit Count
- 30
- Registration Number
- NCT01239472
- Locations
- 🇧🇷
Santa Casa de Misericórdia de Belo Horizonte, Belo Horizonte, Minas Gerais, Brazil
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.